Posted on April 4th, 2019 in
Events
Targeting Deubiquitylases (DUBs): Opportunities for Collaborative Drug Discovery Ubiquigent's Scientific and Business Development Director, Dr Jason Brown, will be presenting at the CHI Drug Discovery Chemistry conference in San Diego on Thursday 11th April 2019 at 11:45am. We will discuss…
Read more
Posted on March 1st, 2019 in
Events
Jason Brown will be presenting at the upcoming European Protein Degradation Congress (May 22nd-23rd, Basel). Modulating protein degradation pathways potentially offers us new ways to address challenging drug targets. Jason Brown will be presenting on our approaches in this field at…
Read more
Posted on October 10th, 2018 in
Events
Ubiquigent will be attending the upcoming Targeted Protein Degradation conference in Boston, MA. Jason Brown (Scientific and Business Development Director) will also be presenting on day one of the conference at 10am: 'Case Study: A chemistry and Assay Platform for…
Read more
Posted on August 22nd, 2018 in
News
Dundee, UK – 22nd August 2018: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services, research tools and novel targeted chemistry, announced today that it has launched REDOXprofiler™. The new service, validated following a collaboration with…
Read more
Posted on August 15th, 2018 in
News
Dundee, UK, 15th August 2018: Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system targeted drug discovery, announced today that it was awarded a new grant from Innovate UK as part of its Investor Accelerator Pilot to support…
Read more
Posted on May 11th, 2018 in
Events
Ubiquigent will be attending Bio 2018 (Boston, June 4th - 7th) to discuss how we enable and support ubiquitin system drug discovery. Our biology and chemistry platforms allow us to design and develop novel compounds targeted towards ubiquitin system proteins as…
Read more
Posted on April 5th, 2018 in
News
Dundee, UK, 5th April 2018: Ubiquigent Limited announced today that it has entered into a multi-year strategic R&D collaboration agreement with FORMA Therapeutics for the design and development of novel deubiquitylase (DUB) enzyme inhibitors. Under the terms of the collaboration…
Read more
Posted on March 30th, 2018 in
Events
'Chemical Libraries to Unlock Deubiquitylase (DUB) Targeted Drug Discovery' Ubiquigent's Scientific Director Dr Jason Brown will be presenting at the CHI Drug Discovery Chemistry conference in San Diego on Thursday 5th April 2018: 'Chemical Libraries to Unlock Deubiquitylase (DUB) Targeted…
Read more
Posted on January 16th, 2018 in
News
Posted on November 29th, 2017 in
Events
“PROTACs – An exciting therapeutic modality” Ubiquigent will be attending and presenting at the upcoming ELRIG networking event, organised in association with AstraZeneca The event is free to attend and will be held at the Alderley Park Conference Centre on…
Read more
